PAR
Click for more information
0.00% 26.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-4094

  1. m931392
    123 Posts.
    lightbulb Created with Sketch. 10
    clock Created with Sketch.
    17/05/24
    12:23
    Post #: 73876840
    Organogenesis ran a successful FDA approved phase 3 trial in the US, which is more than PAR has done.
    PAR Price at posting: 28.0¢ Sentiment: Sell Disclosure: Held
    Likes Created with Sketch. 4  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

NEWS Trending Thread: $13.0 million Institutional Placement
right-arrow Created with Sketch.
NEWS Thick and high-grade copper intersections from surface confirm the potential of Chinook as an open-pit, potential starter mine
right-arrow Created with Sketch.
NEWS Form 20-F filed to explore U.S. market opportunities through proposed Nasdaq ADS listing, aligning with strategic global growth goals
right-arrow Created with Sketch.
LGP Record revenue of $10.2 million as European demand drives 40% quarterly growth, with $1 million in operating cash inflow and $0.5 million in cost savings forecast
right-arrow Created with Sketch.
NVU Nanoveu commences crucial benchmark testing for System-on-aChip (SoC) Semiconductor technology
right-arrow Created with Sketch.
NEWS Oversubscribed share purchase plan successfully raises $2.3 million, with all applications accepted in full
right-arrow Created with Sketch.
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
26.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $92.81M
Open High Low Value Volume
27.0¢ 29.0¢ 25.5¢ $430.3K 1.585M

Buyers (Bids)

No. Vol. Price($)
1 5500 26.0¢
 

Sellers (Offers)

Price($) Vol. No.
26.5¢ 36162 3
View Market Depth
Last trade - 16.10pm 18/10/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.